CCDC108 Inhibitors
Chemical inhibitors of CCDC108 employ various molecular mechanisms to disrupt the signaling pathways and cellular processes essential for the protein's activity. Wortmannin and LY294002 are chemicals that target phosphoinositide 3-kinases (PI3K), a group of enzymes involved in cellular functions such as growth, proliferation, differentiation, motility, and survival. By inhibiting PI3K, these chemicals can hinder the downstream signaling that might regulate CCDC108, leading to a decrease in its functional activity. Staurosporine, a broad-spectrum protein kinase inhibitor, and Go6983, a broad-spectrum protein kinase C (PKC) inhibitor, along with Chelerythrine and Bisindolylmaleimide I, which are more specific PKC inhibitors, interfere with the phosphorylation events that are critical for protein functions. If CCDC108's activity is contingent upon such kinase-mediated modifications, the presence of these inhibitors can significantly reduce its functionality.
Other inhibitors act on different facets of cellular signaling that can affect CCDC108. U73122, which inhibits phospholipase C (PLC), can alter the production of diacylglycerol and inositol trisphosphate, second messengers that participate in the regulation of numerous proteins, possibly including CCDC108. MAP kinase pathway inhibitors such as PD98059, SB203580, and SP600125 target distinct kinases-MEK, p38 MAP kinase, and JNK, respectively. By blocking these kinases, the inhibitors can disrupt the signaling cascades that CCDC108 may rely on. Y-27632, a ROCK inhibitor, could impair cytoskeletal organization and cell motility processes, which are sometimes critical for the proper functioning of certain proteins. Similarly, NSC23766, which inhibits Rac1 GTPase, can disrupt actin cytoskeletal rearrangements, potentially impacting the activity of CCDC108 if it is dependent on such cellular dynamics. Each chemical, through its unique mode of action, can contribute to the inhibition of CCDC108, reflecting the complex network of signaling pathways that govern its activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K). Since CCDC108 is involved in cellular processes that may be regulated by PI3K signaling, inhibiting PI3K can lead to a downstream reduction in CCDC108 activity due to alteration in intracellular signaling and trafficking pathways that are necessary for CCDC108's function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Similar to Wortmannin, LY294002 is another chemical inhibitor of PI3K. By inhibiting PI3K, LY294002 disrupts the downstream signaling pathways that are required for the proper functioning of CCDC108, thus leading to its functional inhibition. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a non-selective inhibitor of protein kinases. CCDC108, as part of its function, may interact with kinase-dependent signaling pathways. By broadly inhibiting these kinases, staurosporine can disrupt these pathways, potentially leading to a decrease in CCDC108 activity due to altered phosphorylation states of either CCDC108 itself or its interacting partners. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go6983 is a broad-spectrum protein kinase C (PKC) inhibitor. If CCDC108's function is PKC-dependent, either directly or indirectly, Go6983 can inhibit this protein by disrupting PKC-mediated signaling, which may be essential for CCDC108's role in the cell. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Chelerythrine is another inhibitor of PKC. By inhibiting PKC, chelerythrine can disrupt the signaling pathways that may be necessary for the function of CCDC108, leading to its functional inhibition. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of PKC. It inhibits CCDC108 by blocking PKC-mediated pathways that may be involved in the regulation and function of CCDC108. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. If the CCDC108 function is associated with the MAPK/ERK pathway, PD98059 would inhibit this protein by blocking the signaling required for its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 acts as an inhibitor of p38 MAP kinase. CCDC108 may rely on p38 MAPK signaling for its function. By inhibiting p38 MAPK, SB203580 can disrupt the signaling pathways necessary for CCDC108's activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). It can inhibit CCDC108 by blocking JNK signaling pathways that could be crucial for the functioning of CCDC108. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is an inhibitor of the Rho-associated protein kinase (ROCK). By inhibiting ROCK, Y-27632 could disrupt cytoskeletal organization and cell motility processes that may be essential for the function of CCDC108. | ||||||